Gene · 442900
Papers2,392
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,392
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MicroRNA profiles as diagnostic tools in pediatric acute lymphoblastic leukemia. | Clin Chim Acta | 2027 | 42641935 | PubTator, text mining | PubMed |
| Tear MicroRNA-Based Molecular Signature for Keratoconus Stratification: A Cross-Cohort Integration Study. | Bioinform Biol Insights | 2026 | 42732169 | PubTator, text mining | PubMed |
| MiR-326 targets ETS1 to activate PI3K/Akt signaling and promote malignant phenotypes in gastric cancer cells. | Pak J Pharm Sci | 2026 | 42708789 | PubTator, text mining | PubMed |
| mi-RNA-mRNA Alterations in Sorted T-Cells of Acquired Aplastic Anemia: Validating the Observations of a Pilot Study. | Int J Lab Hematol | 2026 | 42604788 | PubTator, text mining | PubMed |
| Advances in miRNA-Mediated Bidirectional Crosstalk and Immune Evasion Mechanisms Between Lung Cancer Cells and CD8+ T Cells. | Int J Mol Sci | 2026 | 42589572 | PubTator, text mining | PubMed |
| Immune, metabolic, and steroidogenesis-associated profiles of miR-940, miR-375, and miR-326 in adrenocortical carcinoma. | Integr Biol (Camb) | 2026 | 42537012 | PubTator, text mining | PubMed |
| MicroRNA Expression Profiles as Biomarkers of Response to Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review. | Int J Mol Sci | 2026 | 42511484 | PubTator, text mining | PubMed |
| MicroRNA-326 as a Tumor Suppressor Regulates the NOB1 Expression in Breast Cancer. | Int J Breast Cancer | 2026 | 42494801 | PubTator, text mining | PubMed |
| MicroRNA profiles as quality biomarkers in stored blood components: A narrative review. | Vox Sang | 2026 | 42481401 | PubTator, text mining | PubMed |
| Increased Expression of miR-326 Mediates Chemosensitivity in Pediatric Acute Lymphoblastic Leukemia Through ABCA2 and YY1 Downregulation: An Observational and Experimental Study. | Health Sci Rep | 2026 | 42376363 | PubTator, text mining | PubMed |
| Clinical significance of LINC01093 in children with severe pneumonia and its regulation of miR‑326/MAPK1 axis. | BMC Pediatr | 2026 | 42304299 | PubTator, text mining | PubMed |
| Exploration of miR-326 delivery via biocompatible polymeric nanoparticles in medulloblastoma: A preliminary study. | Mol Ther Nucleic Acids | 2026 | 42233108 | PubTator, text mining | PubMed |
| CircRNA profiles of extracellular vesicle-enriched fractions from ART suppressed pregnant women living with HIV identifies interactome networks key to inflammation and viral latency. | J Transl Med | 2026 | 42231329 | PubTator, text mining | PubMed |
| Functional and mechanistic inactivation of immune hubs orchestrates tumor development and progression in lung adenocarcinoma. | Discov Oncol | 2026 | 42174277 | PubTator, text mining | PubMed |
| Statement of Retraction: Long non-coding RNA LINC01270 is an onco-promotor in lung adenocarcinoma by upregulating LARP1 via sponging miR-326. | Bioengineered | 2026 | 42165255 | PubTator, text mining | PubMed |
| HERV2365 upregulates FGF1 expression by sponging miR-326 to promote the progression of intrahepatic cholangiocarcinoma. | iScience | 2026 | 42164859 | PubTator, text mining | PubMed |
| MicroRNA profiles in multiple sclerosis: A review of the literature. | J Neuroimmunol | 2026 | 42066703 | PubTator, text mining | PubMed |
| Extracellular Vesicles From Metabolically Healthy Obesity Convey Distinct Molecular Signals That Initiate Endothelial Dysfunction: A Multi-Omics Study in Adults of African Ancestry. | bioRxiv | 2026 | 42039647 | PubTator, text mining | PubMed |
| Retraction notice to "miR-326 functions as a tumor suppressor in human prostatic carcinoma by targeting Mucin1" [Biomedicine & Pharmacotherapy 108 (2018) 574-583]. | Biomed Pharmacother | 2026 | 42020217 | PubTator, text mining | PubMed |
| Emerging miRNA biomarkers in breast cancer: The role of miR-223, miR-326, and miR-429 in tumor profiling. | Mol Biol Rep | 2026 | 41920379 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/442900/papers